Several events occur during the first months of life that allow the immune system to become competent and functional. The aim of this article is to review the rationale and evidence of an influence of (n-3) long-chain PUFA (LCPUFA) on the immune system of infants. The (n-3) LCPU-FA exert their immunomodulatory activities at different levels. The (n-3) LCPUFA metabolites induce eicosanoid production, alter gene expression, and modify lipid raft composition, altering T-cell signalling; all contribute to immunological functional changes. However, the roles of these mechanisms and the types of T or other immunological cells involved remain unclear at present. Moreover, the effect of (n-3) LCPUFA on the immune system of infants may vary according to dose, time of exposure, and profile of the immune system (T-helper, Th1/Th2). Most of the interventional studies in infancy have been performed for the prevention of allergy. They all confirmed influence on T-cell function and cytokine profiles, but clinically beneficial effects are more conflicting. Supplementation of the maternal diet in pregnancy or early childhood with (n-3) LCPUFA is potentially a noninvasive intervention strategy to prevent the development of allergy, infection, and possibly other immune-mediated diseases. However, any long-term in vivo effects on (n-3) LCPUFA early in life for immunomodulatory defense in infants and later on immune status and health remain to be assessed. 
PRODUCT NEWS

ACCURATE ALLERGEN IDENTIFICATION NOW A REALITY
Labspec (Pty) Ltd is pleased to announce the launch of a national allergen-testing awareness campaign across South Africa, to let consumers and medical practitioners alike know that highly accurate, specific allergen identification is now within everyone's reach.
Being able to identify exactly which allergen elicits an allergic response within an individual, may result in more specific treatment, an accurate overview of any lifestyle changes that may need to be made in the affected individual, and ultimately, enhanced quality of life.
As a subsidiary of Phadia, the world leader in diagnostics, Labspec is committed to helping medical practitioners make accurate diagnoses and sound management decisions.
We at Labspec have also initiated a national print media campaign both to consumers and medical staff, and a dedicated sales force will highlight the benefits to paediatricians and general practitioners across the country.
Possibly the best part of requesting a Labspec allergen test, is the fact that the procedure is covered by most medical aids, thereby making the decision of whether to be tested or not, an easy one.
Please contact Labspec on 011-792-6790/1/2/3, or visit www.labspec.co.za.
Contact:
Charles Duff 011-792-6790/1/2/3
Maria Ramsay 082-410-6053
Angela Neveling 083-407-7654
Jacque Larsen 083-273-2604
A P H A D I A C O M PA N Y
GIVING TODDLERS A HEAD START IN LIFE
Abbott, leaders in Science-Based Nutrition, are proud to announce the launch of Isomil 3 Advance Plus, the first soybased follow-on formula to contain the essential long-chain polyunsaturated fatty acids, arachidonic acid (ARA) and docosahexaenoic acid (DHA). The importance of DHA and ARA, naturally found in breast milk and added to infant formulas to support brain development, was recognised by the rapid accretion of these fatty acids in the infant brain. 1,2 Reports of enhanced intellectual development in breastfed children and the recognition of the physiological importance of DHA in visual and neural systems, led to clinical trials that evaluated whether infant formulas supplemented with DHA and ARA would enhance visual and cognitive development. 1 Evidence for a beneficial effect of ARA plus DHA supplementation on central nervous system (CNS) development is strong. 3 A randomised study evaluated visual and cognitive development in infants at 14 and 39 months of age and compared infants fed standard formula, formula supplemented with DHA or formula supplemented with DHA and ARA. 1 This study, with the longest follow-up period reported to date, showed that DHA and ARA supplementation support visual and cognitive development in infants from birth to children 39 months of age. 1 Isomil 3 Advance Plus is a milk-and lactose-free, soy-based formula that is specifically designed for children from 1 year of age who have IgE-mediated cow's milk allergy, are lactose intolerant or suffer from digestive symptoms such as gas, diarrhoea or regurgitation. 4 In addition to the patented combination of DHA and ARA, Isomil 3 Advance Plus contains:
• Taurine and choline, which together with DHA and ARA are required for brain development. 5, 6 • Soy protein isolate, equivalent to animal protein in quality and a rich source of nucleotides, required for normal immune development. 7 • A vegetable oil blend that optimizes calcium and fat absorption and is associated with a lower incidence of gastrointestinal intolerance than infant formulas containing animal fats or palm olein oil. 8 Stool characteristics of infants fed with this unique vegetable oil blend closely resemble those of infants fed human milk.
PRODUCT NEWS
MIELE LAUNCHES TOP-CLASS RANGE OF VACUUM CLEANERS
A fact of modern life is the increase in allergies, with more and more adults and children suffering from asthma, rhinitis and hay fever. Allergies are made worse by household pets, and dust mites in carpets, mattresses and soft furnishings. In response to the growing need for appliances that can help alleviate the problems suffered by allergy sufferers Miele have developed a number of features and accessories to ensure excellent levels of cleanliness in the home. 
BOEHRINGER INGELHEIM LAUNCHES INFLANAZE ® 100.
It is with great pleasure and excitement that Boehringer Ingelheim, a leader in respiratory care, announces the launch of Inflanaze ® 100.
Allergic rhinitis is a highly prevalent chronic respiratory disease that impacts significantly on the quality of life of patients. 1 The prevalence of allergic rhinitis is rising with a huge indirect and direct economic burden. 1 In addition nearly 80 % of asthmatic patients have coexisting allergic rhinitis.
2 Topical corticosteroids are highly effective first-line treatment of allergic rhinitis. 3 Budesonide is comparatively an effective corticosteroid which is well tolerated for all classifications of allergic rhinitis. 4 
Inflanaze
® 100, 100µg budesonide per metered spray, provides another option for healthcare professionals to treat this common respiratory disease. Inflanaze ® 100 provides high dose budesonide for the allergic rhinitis patient and allows tapering down of medication to the lowest dose adequate to control symptoms. 5 With its less number of sprays per day, the new 100 dosage allows for better patient compliance.
1 It is registered from the age of 6 years allowing for use in children. Inflanaze ® 50 and 100 possess a broad actuator making the administration of medication to children and patients who struggle to use nasal sprays easy and comfortable. Inflanaze ® 100 contains 200 doses, contains no alcohol and has potassium sorbate as its preservative. 6 This product addition shows that Boehringer Ingelheim, with its wide range of medication for asthma and allergic rhinitis, is committed to optimising respiratory care. Studies have shown improvements in symptom and activity scores from as early as day one, affirming the efficacy of SINGULAIR 4 mg in this age group. 3 The current guidelines for treatment of asthma in children, as compiled by the Allergy Society of South Africa (ALLSA), call for the introduction of a leukotriene antagonist as a controller agent in this age group at step 2, after the use of short-acting reliever medication has proven to be inadequate in controlling asthma symptoms. In other words using leukotriene antagonist as a first line controller agent. 4 At present, of the leukotriene receptor antagonists, only SINGULAIR is indicated for use in children under the age of 12.
2 SINGULAIR 4 mg is indicated for the prophylactic treatment of mild to moderate asthma in the 2-5 year old age group. SINGULAIR 4 mg is presented in a 28-day pack and one tablet should be taken once daily at bedtime. 2 To date worldwide use is more than 2.2 million children in more than 90 countries. This puts SINGULAIR in the unique position of being the only controller therapy to be registered and indicated for asthmatic patients from 2 years old and up. 
